A lesion- and pathogen-targeted antibiotic-free phototheranostic platform based on Treponema pallidum-activated macrophage membranes for syphilis lesion treatment
Benzathine penicillin G (BPG) is the first-line therapy for syphilis; however, its widespread application is significantly hampered by allergic reactions and unpredictable supply chain disruptions. These limitations pose substantial clinical and public health challenges, particularly in resource-limited settings where syphilis remains endemic. To address these limitations, we developed a lesion- and pathogen-targeted phototheranostic platform (BDP@TM NPs) for the treatment of syphilis by integrating an aggregation-induced emission phototherapeutic agent borondipyrromethene (BDP) into T. pallidum -preactivated macrophage membranes. BDP@TM NPs retained adhesion molecules and a TLR2-enriched membrane phenotype derived from preactivated macrophages, which were associated with enhanced accumulation at syphilitic lesions and increased interaction with T. pallidum , thereby enhancing the combined photothermal and photodynamic antibacterial activity. This treatment exhibited therapeutic effects approaching that of BPG for local lesion regression in the rabbit primary-lesion model. More importantly, BDP@TM NPs can interact with activated vascular endothelial cells at the infected site, reducing T. pallidum adhesion and potentially limiting pathogen dissemination. This study pioneers the integration of membrane biomimetic strategies with photo-driven theranostics, offering an innovative antibiotic-free paradigm for primary syphilis lesion management and providing a basis for further preclinical development. BDP NPs are combined with membranes from Treponema pallidum-activated macrophages to form BDP@TM NPs. In a rabbit model of primary syphilis, the nanoparticles target lesions, bind to the bacteria, and enable imaging-guided killing under an 808 nm NIR laser through photothermal and photodynamic therapy
Authors
- Juewei Ning (ORCID: https://orcid.org/0000-0002-7136-9011)
- Qin Zeng (ORCID: https://orcid.org/0000-0001-5854-7584)
- Minying Li (ORCID: https://orcid.org/0000-0001-8389-0544)
- Yuhui Liao (ORCID: https://orcid.org/0000-0003-4702-9516)
- Xu Chen (ORCID: https://orcid.org/0000-0002-4685-5456)
- Yunxia Wu (ORCID: https://orcid.org/0009-0003-6014-9472)
- Qiulin Xie
- Minghai Zhao
- Jinxiong Lin
- Zeyu Liu
- Judun Zheng
- Jialin Huang
- Wei Wang
- Xipeng Li
Institutions
- Kunming Medical University (CN)
- Gannan Medical University (CN)
- Ningxia Medical University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s12951-026-05218-z
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00